Off-label uses of Bevacizumab: breast and lung cancer indications

BlueCross BlueShield Association

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

The BlueCross BlueShield Association Technology Evaluation Center website (www.bcbs.com/tec) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website.

Citation

Authors’ objectives
This assessment summarizes and evaluates evidence on outcomes of bevacizumab for breast cancer and non-small cell lung cancer (NSCLC). For both cancers, evidence on bevacizumab is assessed separately as second- or subsequent-line therapy for advanced or metastatic disease, as first-line therapy for advanced or metastatic disease, or as adjuvant therapy for early stage disease. Another Assessment (Vol. 21, No. 9) summarizes and evaluates evidence on health outcomes of bevacizumab for clear cell renal carcinoma and other malignancies besides colorectal cancers.

Project page URL
http://www.bcbs.com/blueresources/tec/contact-tec.html

Indexing Status
Subject indexing assigned by CRD

MeSH
Antibodies, Monoclonal /therapeutic use; Breast Neoplasms /drug therapy; Lung Neoplasms /drug therapy

Language Published
English

Country of organisation
United States

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com

AccessionNumber
32007000053

Date bibliographic record published
07/02/2007

Date abstract record published
07/02/2007